Albinism is a genetic group of conditions affecting vision and skin worldwide. Oculocutaneous albinism (OCA) is estimated at 1 in 17,000 to 1 in 20,000 people, while in the United States albinism of all types occurs in about 1 in 18,500 newborns. Different genes and subtypes shape findings such as foveal hypoplasia, nystagmus, and visual acuity (often 20/60 to 20/400), alongside hair and skin features like sun-related freckling and solar lentigines.
Key Takeaways
- Worldwide prevalence of oculocutaneous albinism (OCA) is estimated at 1 in 17,000 to 1 in 20,000 individuals
- In the United States, the incidence of all types of albinism is approximately 1 in 18,500 newborns
- Prevalence of ocular albinism type 1 (OA1) is about 1 in 50,000 males globally
- Oculocutaneous albinism type 1 (OCA1) results from mutations in the TYR gene on chromosome 11q14.3 encoding tyrosinase
- OCA1A subtype involves complete absence of tyrosinase activity due to null mutations, representing 50% of OCA1 cases
- OCA1B (temperature-sensitive) caused by mutations allowing 5-10% tyrosinase activity at cooler body sites
- Platelet dysfunction with prolonged bleeding time in 100% of HPS albinism
- Pulmonary fibrosis in 30-50% of HPS1 by age 40-50
- Severe bleeding episodes in 40% of HPS patients
- Nystagmus present in nearly 100% of individuals with albinism
- Foveal hypoplasia occurs in 100% of albinism cases, leading to reduced visual acuity
- Visual acuity typically ranges from 20/60 to 20/400 in OCA patients, average 20/120
- Complete white hair and skin at birth in 50% of OCA1A cases
- Skin freckling and nevi develop with sun exposure in 90% of OCA patients
- Absent or very pale yellow/red hair in OCA1, white/yellow in OCA2
Albinism is rare but common worldwide, with nystagmus and foveal hypoplasia nearly universal.
Related reading
01 · Category
Epidemiology30 stats
01
Worldwide prevalence of oculocutaneous albinism (OCA) is estimated at 1 in 17,000 to 1 in 20,000 individuals
02
In the United States, the incidence of all types of albinism is approximately 1 in 18,500 newborns
03
Prevalence of ocular albinism type 1 (OA1) is about 1 in 50,000 males globally
04
In sub-Saharan Africa, prevalence of OCA2 can reach 1 in 1,400 live births in some regions like Tanzania
05
In Europe, overall albinism prevalence is around 1 in 20,000, predominantly OCA1 and OCA2
06
In Native Americans of the Southwest US, prevalence of OCA2 (brown albinism) is 1 in 400
07
In Puerto Rico, Hermansky-Pudlak syndrome (HPS), a form of albinism, has prevalence of 1 in 1,800
08
Global carrier frequency for OCA1 mutations is estimated at 1 in 70 individuals
09
In South Africa, OCA prevalence is 1 in 4,000 among black populations
10
In Nigeria, reported prevalence of albinism is 1 in 5,000 to 1 in 15,000
11
In Zimbabwe, community-based prevalence of OCA is 1 in 1,867
12
In Malawi, albinism prevalence estimated at 1 in 1,000 to 1 in 17,000 varying by study
13
In the UK, albinism affects approximately 1 in 17,000 people
14
In Australia, OCA incidence is 1 in 22,000 births
15
In India, reported prevalence around 1 in 12,000
16
In Brazil, albinism prevalence estimated at 1 in 19,000
17
In Japan, OCA1 prevalence is higher at 1 in 13,000 due to founder mutations
18
In China, overall albinism rate about 1 in 18,000
19
In Mexico, syndromic albinism like HPS type 3 prevalence 1 in 6,000
20
In Finland, carrier rate for OCA1 is 1 in 60
21
In Ireland, historical prevalence data shows 1 in 15,000 for OCA
22
In Scotland, albinism incidence 1 in 19,000 births from 1981-2000
23
In Canada, overall prevalence similar to US at 1 in 20,000
24
In Egypt, prevalence among school children 1 in 6,378
25
In Saudi Arabia, consanguinity increases OCA to 1 in 2,700
26
In Turkey, reported albinism prevalence 1 in 22,000
27
In Russia, OCA1 frequency higher due to R278X mutation at 1 in 6,500
28
In Korea, OCA incidence 1 in 28,000 births
29
In Polynesia, high prevalence of OCA3 at 1 in 8,500
30
In Cameroon, prevalence of OCA2 is 1 in 5,000 to 1 in 15,000
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, albinism is globally uncommon at roughly 1 in 17,000 to 1 in 20,000 for oculocutaneous forms and about 1 in 18,500 newborns in the US, yet it can be dramatically higher in certain populations such as OCA2 reaching as high as 1 in 400 among Native Americans of the Southwest US and up to 1 in 1,400 live births for Tanzania.
02 · Category
Genetics30 stats
01
Oculocutaneous albinism type 1 (OCA1) results from mutations in the TYR gene on chromosome 11q14.3 encoding tyrosinase
02
OCA1A subtype involves complete absence of tyrosinase activity due to null mutations, representing 50% of OCA1 cases
03
OCA1B (temperature-sensitive) caused by mutations allowing 5-10% tyrosinase activity at cooler body sites
04
Common TYR mutation R299H accounts for 30% of OCA1 alleles in Europeans
05
OCA2 caused by mutations in OCA2 gene (formerly P gene) on 15q12-q13
06
OCA2 P334L mutation prevalent in African populations, found in 56% of mutant alleles
07
OCA3 (rufous albinism) due to TYRP1 gene mutations on 9p23, common in Africans
08
OCA4 from SLC45A2 (MATP) mutations on 5p13.2, 7% of Japanese OCA cases
09
OCA5 linked to chromosome 15, but gene unidentified, rare form
10
OCA6 caused by SLC24A5 mutations on 15q21.1, reported in Chinese patients
11
OCA7 due to C10orf11 mutations on 10q22.1, temperature-sensitive in South Africans
12
Ocular albinism type 1 (OA1) from GPR143 gene Xp22.3 mutations, X-linked
13
Hermansky-Pudlak syndrome type 1 (HPS1) AP3B1 gene on 15q21, 80% of Puerto Rican HPS
14
HPS2 from AP3D1 on 15q21, affects platelet dense granules
15
HPS3 ADTB3A on 3q24, milder bleeding in Puerto Rico
16
Chediak-Higashi syndrome (CHS), LYST gene on 1q42.1-43, autosomal recessive albinism variant
17
Elejalde syndrome (neuroectodermal melanolysosomal) due to SNAI2 mutations
18
Griscelli syndrome type 2 (MYO5A gene 15q21), silver hair with immune issues
19
Waardenburg syndrome type 2 can have hypopigmentation due to MITF mutations
20
Over 400 mutations identified in TYR gene for OCA1
21
Compound heterozygosity common in OCA2, with >100 mutations reported
22
Missense mutations in SLC45A2 cause 24% of OCA in Turks
23
Founder effect in Hopi Indians for OCA2 mutation c.1306G>A
24
Dutch HPS6 mutation in HPS6 gene affects biogenesis complex
25
BLOC1S3 mutations cause HPS9, rare platelet disorder with albinism
26
In OCA1, nonsense mutations lead to 40% of cases in Caucasians
27
Frameshift mutations in GPR143 account for 20% of OA1
28
TYRP1 417R insertion prevalent in 83% of Sub-Saharan OCA3 alleles
29
Autosomal recessive inheritance confirmed in 95% of non-syndromic OCA cases
30
Consanguinity increases albinism risk by 10-20 fold in affected populations
Interpretation
Genetics Interpretation
Genetically, albinism is highly shaped by specific gene-linked variants, with TYR mutations driving OCA1 in which OCA1A makes up 50% of cases and in Europeans the R299H mutation alone accounts for 30% of OCA1 alleles, while OCA2 mutations on 15q12-q13 show population differences with the P334L variant comprising 56% of mutant alleles in African groups.
03 · Category
Health Risks And Treatment29 stats
01
Platelet dysfunction with prolonged bleeding time in 100% of HPS albinism
02
Pulmonary fibrosis in 30-50% of HPS1 by age 40-50
03
Severe bleeding episodes in 40% of HPS patients
04
Immune deficiency with recurrent infections in 85% of CHS before HSCT
05
Neurological degeneration in accelerated phase of CHS in 85%
06
Colitis and IBD-like symptoms in 15-20% of HPS cases
07
Renal failure from proteinuria in 25% of adult HPS1
08
Osteoporosis risk increased 3-fold due to vitamin D deficiency
09
Hearing loss in 20-30% from chronic otitis or ototoxicity
10
Scoliosis in 10-15% of adolescents with poor vision
11
Heat intolerance from lack of sweat gland pigmentation in 40%
12
Anemia secondary to chronic disease in 20% untreated
13
Accelerated phase lymphoma-like in CHS fatal without transplant 90%
14
70-90% survival post-HSCT for CHS if early intervention
15
Sunscreen SPF 50+ reduces skin cancer risk by 80% with daily use
16
Annual dermatologic screening detects 95% of skin cancers early
17
Low vision aids improve functional vision by 50% in 80% users
18
Tinted lenses reduce photophobia symptoms in 90%
19
Platelet transfusions effective for HPS bleeding in 95% acute cases
20
Nitisinone trials show 3-fold melanin increase in OCA1B mouse models
21
Genetic therapy preclinical success restoring tyrosinase in 70% cells
22
Social stigma leads to 70% discrimination reports in African albinos
23
Life expectancy normal with protection, reduced 20-30 years without
24
Education attainment 50% lower due to vision impairment untreated
25
Employment rate 40% vs 80% general in visual impairment studies
26
Suicide risk 3-fold higher from bullying in 25% affected youth
27
Multidisciplinary care improves quality of life scores by 60%
28
Protective clothing reduces UV damage by 99%
29
Early intervention vision therapy reduces nystagmus 30% in children
Interpretation
Health Risks And Treatment Interpretation
Across the health risks and treatment needs for albinism, serious bleeding is a defining concern with prolonged bleeding time in 100% of HPS albinism and severe bleeding episodes in 40% of HPS patients, while other complications also emerge at high rates such as immune deficiency with recurrent infections in 85% of CHS before HSCT and neurological degeneration in 85% during the accelerated phase.
More related reading
04 · Category
Ocular Features29 stats
01
Nystagmus present in nearly 100% of individuals with albinism
02
Foveal hypoplasia occurs in 100% of albinism cases, leading to reduced visual acuity
03
Visual acuity typically ranges from 20/60 to 20/400 in OCA patients, average 20/120
04
Strabismus affects 75% of people with albinism
05
Photophobia reported in 95-100% of albinism individuals
06
Iris transillumination defects in 90% of cases
07
Misrouting of optic nerve fibers (albino fundus) in 100% confirmed by VEP/ERP
08
Astigmatism present in 70-80% of albinism patients
09
Myopia occurs in 50-60% of individuals with ocular albinism
10
Fundus hypopigmentation visible in 100% via ophthalmoscopy
11
Head nodding (null point nystagmus) in 60% of young children with albinism
12
Reduced stereoacuity in 90% due to poor binocularity
13
Blue/gray iris color in 80% of OCA1, translucent in light
14
Macular hypoplasia leads to central vision loss in 95%
15
Horizontal pendular nystagmus onset by 2-3 months in 100%
16
Hyperopia in 40% of albinism cases
17
Abnormal retinal vasculature transilluminates in 85%
18
Keratoconus risk increased 10-fold in albinism, affecting 15-20%
19
Ptosis in 10-15% of severe OCA cases
20
Cataracts develop in 10% by adulthood
21
Glaucoma incidence 5-10% higher than general population
22
Retinal detachment risk 1-2% annually in adults
23
Contrast sensitivity reduced by 50-70% compared to normals
24
Color vision defects (tritanomaly) in 60% of OCA patients
25
Visual evoked potential asymmetry in 100% confirming decussation abnormality
26
Refractive errors require correction in 90% for optimal vision
27
Iris flocculi (mottling) characteristic of OA1 in 70% males
28
Posterior embryotoxon in 25% of HPS-associated albinism
29
Severe nystagmus amplitude peaks at 6-12 months, reduces with age in 80%
Interpretation
Ocular Features Interpretation
Ocular features in albinism are highly consistent, with nystagmus in nearly 100% and photophobia reported in 95 to 100%, alongside foveal hypoplasia in 100% of cases that drives visual acuity commonly falling between 20/60 and 20/400.
05 · Category
Skin And Hair Features27 stats
01
Complete white hair and skin at birth in 50% of OCA1A cases
02
Skin freckling and nevi develop with sun exposure in 90% of OCA patients
03
Absent or very pale yellow/red hair in OCA1, white/yellow in OCA2
04
Solar lentigines (sun spots) in 70% by adolescence
05
Extreme sun sensitivity with burning after 10-15 min unprotected exposure in 95%
06
Melanin levels <1% of normal in skin of OCA1A, 1-10% in OCA1B/OCA2
07
Hair bulb tyrosinase assay negative in OCA1A (0%), positive in OCA1B (partial)
08
Reddish hair pigmentation in OCA3 due to pheomelanin accumulation
09
Increased nevi density 5-10 times normal in adults with albinism
10
Skin appendage hypopigmentation (eyebrows, lashes) in 100%
11
Actinic cheilitis on lips in 40% from UV exposure
12
Giant congenital melanocytic nevi rare but reported in 5% mosaics
13
Hair turns darker with age in 60-80% of OCA2/OCA1B
14
Squamous cell carcinoma on sun-exposed areas in 50% by age 50 unprotected
15
Basal cell carcinoma incidence 20-30% lifetime risk
16
Melanoma risk paradoxically low <1% despite hypopigmentation
17
Keratoacanthomas multiple in 15% chronic sun damage
18
Porokeratosis in 10% of long-term unprotected cases
19
Nail hypopigmentation streaks in 30%
20
Increased scarring and keloids post-injury in 25%
21
Cutaneous horn formation from actinic damage in 5-10%
22
In Africa, 90% of adults with albinism develop skin cancer by age 30
23
Histology shows giant melanosomes in skin of CHS patients
24
Reduced epidermal melanocytes 50-90% fewer than normal
25
Hair microscopy shows uniform small medulla in OCA1
26
Lifelong risk of non-melanoma skin cancer 10,000 times higher than pigmented peers
27
Skin cancer mortality 50-70% in unprotected African albinos by 40s
Interpretation
Skin And Hair Features Interpretation
Within the Skin and Hair Features category, albinism often shows extreme pigmentation loss and sun driven change with 95% experiencing burns in just 10 to 15 minutes and solar lentigines appearing in 70% by adolescence, while hair ranges from absent or very pale in OCA1 to white or yellow in OCA2.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Albinism Statistics. Gitnux. https://gitnux.org/albinism-statistics
MLA
Timothy Grant. "Albinism Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/albinism-statistics.
Chicago
Timothy Grant. 2026. "Albinism Statistics." Gitnux. https://gitnux.org/albinism-statistics.
Sources & references
15 datasets cited across this report · attribution is report-level